New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
Go back to New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 128.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $128.00 | 52 Week High | $118.49 | |||
| Open | $128.00 | 52 Week Low | $55.00 | |||
| Day High | $128.00 | P/E | N/A | |||
| Day Low | $128.00 | EPS | $-0.56 | |||
| Volume | 17 | |||||
